Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14214320 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL11369142 | 0.84 | — | — | |
| SCHEMBL12294017 | 0.81 | LMNA (0.51) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL3983987 | 0.80 | LMNA (0.50) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL3326726 | 0.80 | LMNA (0.53) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL14084024 | 0.80 | LMNA (0.50) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL4951608 | 0.80 | LMNA (0.53) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL3326724 | 0.80 | LMNA (0.53) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL14388719 | 0.77 | NPC1 (0.50) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL11363371 | 0.77 | LMNA (0.45) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | ALDH1A1 778/4885HPGD 416/4885MAPT 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.